DE361977T1 - Peptide mit t-zellensuppressor-wirksamkeit. - Google Patents
Peptide mit t-zellensuppressor-wirksamkeit.Info
- Publication number
- DE361977T1 DE361977T1 DE198989310021T DE89310021T DE361977T1 DE 361977 T1 DE361977 T1 DE 361977T1 DE 198989310021 T DE198989310021 T DE 198989310021T DE 89310021 T DE89310021 T DE 89310021T DE 361977 T1 DE361977 T1 DE 361977T1
- Authority
- DE
- Germany
- Prior art keywords
- asp
- arg
- lys
- val
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000003915 cell function Effects 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Claims (10)
1. Peptid mit der Fähigkeit, die cGMP-Aktivität in der
Human-T-Zellinie CEM zu erhöhen, ausgewählt unter Peptiden der Formel:
R-Arg-X-Asp-Y-NR1 R2
in der
in der
R H, niedriges Alkyl, Acetyl, Formyl, niedriges Alkanoyl ist,
X Pro, Dehydro-Pro, Hydroxyl-Pro, D-Lys, Aib oder Lys
ist,
Y GIy oder die D- oder L-Form einer Aminosäure ist, ausgewählt unter VaI, Ala, He, Leu, Asp, GIu, Gin
oder Lys,
R1 H und R2 niedriges Alkyl oder Alkenyl mit 1 bis 10
Kohlenstoffatomen, zyklisches Alkyl oder Alkenyl mit 4
bis 8 Kohlenstoffatomen, Aryl oder NHR3 ist, wobei R3
niedriges Alkyl mit 1 bis 10 Kohlenstoffatomen, zyklisches
Alkyl oder Alkenyl mit 4 bis 8 Kohlenstoffatomen oder Aryl ist, oder
R1 und R2 zusammen eine Methylenkette mit 4 bis 7
Kohlenstoffatomen bilden.
2. Peptid nach Anspruch 1, dadurch gekennzeichnet, daß X Pro oder Lys und Y VaI ist.
3. Peptid nach Anspruch 1, dadurch gekennzeichnet, daß es unter
Arg-Pro-Asp-Val-Isopropylamid,
Arg-Lys-Asp-Val-Anilinamid,
Formyl-Arg-Pro-Asp-Val-Methylamid, )
Acetyl-Arg-Pro-Asp-Val-Methylamid, &igr;
Arg-Pro-Asp-Val-Methylamid,
Arg-Lys-Asp-Val-Methylamid,
Arg-Lys-Asp-Val-Methylamid,
0381977
Arg-Lys-Asp-Val-2-Phenylhydrazid,
Arg-Lys-Asp-Val-Piperidinamid,
Arg-Lys-Asp-Val-Cyclohexylamid, und Arg-Lys-Asp-Val-Isopropylamid
Arg-Lys-Asp-Val-Cyclohexylamid, und Arg-Lys-Asp-Val-Isopropylamid
ausgewählt ist.
4. Pharmazeutische Zusammensetzung, enthaltend eine therapeutisch wirksame Menge mindestens eines Peptids
nach einem der Ansprüche 1 bis 3 in einer pharmazeutisch verträglichen Formulierung.
5. Zusammensetzung nach Anspruch 4, dadurch gekennzeichnet,
daß sie in einer für die orale Verabreichung geeigneten Form vorliegt.
6. Verfahren zur Herstellung eines Peptids nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß das
Peptid in fester Phase synthetisiert wird.
7. Verfahren zur Herstellung eines Peptids nach einem der
Ansprüche 1 bis 3, dadurch gekennzeichnet, daß das Peptid in Lösung synthetisiert wird.
8. Verwendung eines Peptids nach einem der Ansprüche 1
bis 3 zur Herstellung einer pharmazeutischen Zusammensetzung zur Regulierung des Immunsystems beim Menschen.
9. Verwendung eines Peptids nach einem der Ansprüche 1
bis 3 zur Herstellung einer pharmazeutischen Zusammensetzung zur Regulierung eines Mangels oder Überschusses
an T-Zellfunktion beim Menschen.
10. Verfahren zur Regulierung eines Mangels oder Überschusses an T-Zellfunktion bei einem Patienten,
daduch gekennzeichnet, daß dem Patienten eine therapeutisch wirksame Menge mindestens eines Peptids nach
einem der Ansprüche 1 bis 3 verabreicht wird.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25250588A | 1988-09-30 | 1988-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE361977T1 true DE361977T1 (de) | 1990-09-27 |
Family
ID=22956294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE198989310021T Pending DE361977T1 (de) | 1988-09-30 | 1989-09-29 | Peptide mit t-zellensuppressor-wirksamkeit. |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0361977A3 (de) |
| JP (1) | JPH03502930A (de) |
| KR (1) | KR900701298A (de) |
| CN (1) | CN1041366A (de) |
| AU (1) | AU627781B2 (de) |
| BR (1) | BR8907105A (de) |
| CZ (1) | CZ278982B6 (de) |
| DD (1) | DD297416A5 (de) |
| DE (1) | DE361977T1 (de) |
| DK (1) | DK132390A (de) |
| ES (1) | ES2031803T1 (de) |
| FI (1) | FI902534A0 (de) |
| GR (1) | GR900300088T1 (de) |
| HU (1) | HU205143B (de) |
| IE (1) | IE893110L (de) |
| IL (1) | IL91775A0 (de) |
| MX (1) | MX17750A (de) |
| NZ (1) | NZ230707A (de) |
| PT (1) | PT91846B (de) |
| WO (1) | WO1990003180A1 (de) |
| YU (1) | YU183789A (de) |
| ZA (1) | ZA897282B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639729A (en) * | 1993-08-26 | 1997-06-17 | Immunobiology Research Institute, Inc. | Tripeptides useful in immune and CNS therapy |
| US5936065A (en) * | 1993-12-06 | 1999-08-10 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| US8236766B2 (en) | 2006-11-10 | 2012-08-07 | Cara Therapeutics, Inc. | Uses of synthetic peptide amides |
| CA2667155C (en) | 2006-11-10 | 2016-05-10 | Cara Therapeutics, Inc. | Synthetic peptide amides |
| US8906859B2 (en) | 2006-11-10 | 2014-12-09 | Cera Therapeutics, Inc. | Uses of kappa opioid synthetic peptide amides |
| US7842662B2 (en) | 2006-11-10 | 2010-11-30 | Cara Therapeutics, Inc. | Synthetic peptide amide dimers |
| US7713937B2 (en) | 2006-11-10 | 2010-05-11 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4190646A (en) * | 1975-11-11 | 1980-02-26 | Sloan-Kettering Institute For Cancer Research | Polypeptide compositions and methods |
| US4190647A (en) * | 1979-01-26 | 1980-02-26 | Sloan-Kettering Institute For Cancer Research | Polypeptides and methods |
| US4261886A (en) * | 1980-03-13 | 1981-04-14 | Ortho Pharmaceutical Corporation | Peptides having thymopoietin-like activity |
| FR2460290A1 (fr) * | 1979-06-29 | 1981-01-23 | Rhone Poulenc Ind | Nouveaux tetra- ou pentapeptides, leur preparation et les medicaments qui les contiennent |
| DE2938420A1 (de) * | 1979-09-22 | 1981-04-09 | Hoechst Ag, 6000 Frankfurt | Neue peptide und verfahren zu ihrer herstellung |
| US4309340A (en) * | 1980-03-31 | 1982-01-05 | American Home Products Corporation | Polypeptide compositions |
| HU185263B (en) * | 1981-06-12 | 1984-12-28 | Richter Gedeon Vegyeszet | Process for producing peptides effective on the immuncontroll analogous with the tp5 |
| US4614517A (en) * | 1982-08-04 | 1986-09-30 | La Jolla Cancer Research Foundation | Tetrapeptide |
| US4505853A (en) * | 1983-11-18 | 1985-03-19 | Ortho Pharmaceutical Corporation | Enzyme-resistant immunomodulatory peptides |
| US4547489A (en) * | 1984-06-11 | 1985-10-15 | Ortho Pharmaceutical Corporation | Conformationally restricted thymopentin-like compounds |
| US4629723A (en) * | 1984-06-27 | 1986-12-16 | Ortho Pharmaceutical Corporation | Potent thymopentin analogs |
| NZ229004A (en) * | 1988-05-19 | 1993-09-27 | Immunobiology Res Inst Inc | Tetrapeptides having t cell helper acitivity |
| HU201095B (en) * | 1988-06-14 | 1990-09-28 | Richter Gedeon Vegyeszet | New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions |
-
1989
- 1989-09-13 WO PCT/US1989/004000 patent/WO1990003180A1/en active Application Filing
- 1989-09-13 KR KR1019900701145A patent/KR900701298A/ko not_active Application Discontinuation
- 1989-09-13 HU HU896052A patent/HU205143B/hu not_active IP Right Cessation
- 1989-09-13 BR BR898907105A patent/BR8907105A/pt not_active Application Discontinuation
- 1989-09-13 JP JP1510652A patent/JPH03502930A/ja active Pending
- 1989-09-13 AU AU43464/89A patent/AU627781B2/en not_active Ceased
- 1989-09-19 NZ NZ230707A patent/NZ230707A/xx unknown
- 1989-09-22 YU YU01837/89A patent/YU183789A/xx unknown
- 1989-09-25 IL IL91775A patent/IL91775A0/xx unknown
- 1989-09-25 ZA ZA897282A patent/ZA897282B/xx unknown
- 1989-09-28 PT PT91846A patent/PT91846B/pt not_active IP Right Cessation
- 1989-09-28 DD DD89333073A patent/DD297416A5/de not_active IP Right Cessation
- 1989-09-28 CZ CS895532A patent/CZ278982B6/cs unknown
- 1989-09-29 ES ES198989310021T patent/ES2031803T1/es active Pending
- 1989-09-29 DE DE198989310021T patent/DE361977T1/de active Pending
- 1989-09-29 IE IE893110A patent/IE893110L/xx unknown
- 1989-09-29 MX MX1775089A patent/MX17750A/es unknown
- 1989-09-29 EP EP19890310021 patent/EP0361977A3/de not_active Withdrawn
- 1989-09-30 CN CN89107673A patent/CN1041366A/zh active Pending
-
1990
- 1990-05-22 FI FI902534A patent/FI902534A0/fi not_active Application Discontinuation
- 1990-05-29 DK DK132390A patent/DK132390A/da not_active Application Discontinuation
-
1991
- 1991-07-31 GR GR90300088T patent/GR900300088T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUT54710A (en) | 1991-03-28 |
| BR8907105A (pt) | 1991-02-05 |
| NZ230707A (en) | 1992-12-23 |
| YU183789A (en) | 1991-08-31 |
| IL91775A0 (en) | 1990-06-10 |
| EP0361977A2 (de) | 1990-04-04 |
| GR900300088T1 (en) | 1991-07-31 |
| DD297416A5 (de) | 1992-01-09 |
| MX17750A (es) | 1993-12-01 |
| ES2031803T1 (es) | 1993-01-01 |
| KR900701298A (ko) | 1990-12-01 |
| AU627781B2 (en) | 1992-09-03 |
| CZ278982B6 (en) | 1994-11-16 |
| HU205143B (en) | 1992-03-30 |
| WO1990003180A1 (en) | 1990-04-05 |
| CN1041366A (zh) | 1990-04-18 |
| DK132390D0 (da) | 1990-05-29 |
| EP0361977A3 (de) | 1991-01-09 |
| DK132390A (da) | 1990-07-18 |
| IE893110L (en) | 1990-03-30 |
| AU4346489A (en) | 1990-04-18 |
| JPH03502930A (ja) | 1991-07-04 |
| PT91846B (pt) | 1995-07-03 |
| PT91846A (pt) | 1990-03-30 |
| FI902534A0 (fi) | 1990-05-22 |
| ZA897282B (en) | 1990-07-25 |
| CZ553289A3 (en) | 1994-04-13 |
| HU896052D0 (en) | 1990-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL109403A0 (en) | Oral drug delivery compositions and methods | |
| NZ217280A (en) | Lgrf derivatives and pharmaceutical compositions | |
| ATE67505T1 (de) | Tetrapyrrolverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen. | |
| GB9316895D0 (en) | Hepatoselective insulin analogues | |
| IL69897A (en) | Human pancreatic grf analogs,compositions comprising them and use thereof | |
| KR900003205A (ko) | 제약 화합물 | |
| EP1616571A3 (de) | Lysin enthaltende Peptid zur Behandlung von Herzkrankheiten | |
| DE585300T1 (de) | Galaninantagonist. | |
| IL101764A0 (en) | Grf analogs xi and pharmaceutical compositions containing them | |
| DE361977T1 (de) | Peptide mit t-zellensuppressor-wirksamkeit. | |
| KR880011198A (ko) | 사이클릭 펩타이드 및 이의 제조방법 | |
| KR880012641A (ko) | 아미노산 유도체 | |
| CA1187869A (en) | Deca- undeca- dodeca and tridecapeptides with thymic activity | |
| US6087337A (en) | Method for treating benign and malignant proliferative skin disease | |
| HUP0003357A2 (hu) | Angiogén hatású ciklusos azapeptidek, ezeket hatóanyagként tartalmazó gyógyászati készítmények, eljárás ezek előállítására és alkalmazásuk | |
| DE69025763T2 (de) | Vasodilatierende und immunsupprimierende peptide | |
| EP0328089A3 (de) | LHRH-Analoge reduzierter Grösse | |
| CA1323301C (en) | Thyrotropin-releasing hormone analogs in cns injury | |
| RU95120588A (ru) | Циклогексапептиды, их смеси, способ их получения и применения | |
| FR2684878B1 (fr) | Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation. | |
| EP0346068A3 (de) | D-Cys6-Vasopressin-Antagonisten | |
| KR920700675A (ko) | 발기 기능장해 치료용 약물(칼시토닌 유전자 관련 펩티드) | |
| TH9800EX (th) | เปปไทด์ที่มีฤทธิ์ในการระงับที-เซล | |
| FI942957A (fi) | Menetelmä peptidien valmistamiseksi, joilla on T-soluavustaja-aktiivisuutta | |
| KR890002232A (ko) | 펩타이드 및 그의 제조방법 |